Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients
El-Sabbah, S., Meawed, T., Anis, R., El-Shafey, A., Abdel Galil, S., Nasr, M., El-Mosely, A. (2019). Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients. EKB Journal Management System, 28(1), 47-53. doi: 10.21608/ejmm.2019.282383
Salwa B. El-Sabbah; Takwa El-Sayed Meawed; Reham H. Anis; Abeer M. El-Shafey; Sahar M. Abdel Galil; Mohamad M. Nasr; Amira M. El-Mosely. "Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients". EKB Journal Management System, 28, 1, 2019, 47-53. doi: 10.21608/ejmm.2019.282383
El-Sabbah, S., Meawed, T., Anis, R., El-Shafey, A., Abdel Galil, S., Nasr, M., El-Mosely, A. (2019). 'Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients', EKB Journal Management System, 28(1), pp. 47-53. doi: 10.21608/ejmm.2019.282383
El-Sabbah, S., Meawed, T., Anis, R., El-Shafey, A., Abdel Galil, S., Nasr, M., El-Mosely, A. Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients. EKB Journal Management System, 2019; 28(1): 47-53. doi: 10.21608/ejmm.2019.282383

Clinical Association of Serum Interleukin-17 and Interleukin-6 in Systemic Lupus Erythematosus Patients

Egyptian Journal of Medical Microbiology
Article 7, Volume 28, Issue 1, January 2019, Page 47-53  XML PDF (335.08 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2019.282383
View on SCiNiTO View on SCiNiTO
Authors
Salwa B. El-Sabbah1; Takwa El-Sayed Meawed email 1; Reham H. Anis1; Abeer M. El-Shafey2; Sahar M. Abdel Galil2; Mohamad M. Nasr3; Amira M. El-Mosely1
1Medical Microbiology and Immunology Department; Faculty of Medicine, Zagazig University
2Rheumatology and Rehabilitation Department; Faculty of Medicine, Zagazig University
3Dermatology & Venereology Department; Faculty of Medicine, Zagazig University
Abstract
Background: Management of Systemic Lupus Erythematosus (SLE) would be greatly assisted by certain biomarkers that perfectly reflect changes in disease activity. Objectives: This study was conducted to evaluate the role of IL-17, IL-6 and their ratio in SLE as regard disease activity, central nervous system CNS and renal involvement. Methodology: A case control study including SLE patients were subjected to clinical examination, assessment of SLE disease activity index (SLEDAI) and laboratory investigations versus healthy controls, quantitative determination of serum IL-17A and IL-6 levels by ELISA. Results: Elevated serum IL-17A and IL-6 levels in SLE cases than control. Serum IL-6 level was higher in renal group, whereas, higher serum IL-17 was detected in neurologically affected patients. Conclusion: SLE patients had significantly upregulated IL-17 and IL-6 levels. SLEDAI was significantly positively correlated with IL-17/IL-6 ratio. Thus, IL-17/ IL-6 ratio may accurately characterize Th17-driven disease than serum IL-17 or IL-6 alone.
Keywords
Cytokines; Interleukin-17; Interleukin-6; Systemic Lupus Erythematosus
Statistics
Article View: 57
PDF Download: 35